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The term “immune privilege” was coined to describe weak immunogenicity
(hypo-immunity) that manifests in some transplant settings. We extended this concept to
encompass hypo-immunity that manifests at local sites of inﬂammation relevant to clinical
diseases. Here, we focus on emerging evidence that enhanced tryptophan catabolism is a
key metabolic process that promotes and sustains induced immune privilege, and discuss
the implications for exploiting this knowledge to improve treatments for hypo-immune and
hyper-immune syndromes using strategies to manipulate tryptophan metabolism.
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INTRODUCTION
Immuneprivilege refers to the phenomenonof low immunogenic-
ity associated with certain organs such as the anterior chamber
of the eye, the brain, the testes, and the placenta (Munn and
Mellor, 2006). Mechanistically, immune privilege probably arises
from the combined effects of physical barriers to immunity and
active immune regulatory processes that are particularly potent in
some organs and tissues. The concept of immune privilege can
also be extended to some chronic inﬂammatory syndromes where
enhanced immune regulation (hypo-immunity) manifests as a fac-
tor in disease progression such as persistent infections and cancer
(Mellor and Munn, 2008). In this sense, immune privilege is not
a unique feature of certain specialized tissues; rather, it is a func-
tional state induced by certain conditions in most – perhaps all –
tissues as one consequence of chronic inﬂammation. In this review
we focus on a speciﬁc molecular pathway that creates induced
immune privilege in a range of disease settings involving expres-
sion of the inducible enzyme indoleamine 2,3 dioxygenase (IDO).
When biochemically active the IDO enzyme catabolizes trypto-
phan to produce metabolites known collectively as kynurenines.
Local metabolic effects of IDO-expressing cells exert profound
effects on immune and tissue cells that suppress pro-inﬂammatory
and immune stimulatory responses to a variety of insults. IDO is
not the only molecular pathway able to create immune privilege in
inﬂamed tissues, and several other metabolic pathways have been
linked to regulatory outcomes recently. By focusing exclusively
on the IDO pathway our aim is to use this particular metabolic
pathway to illustrate“good”and“bad”aspects of immuneprivilege
in relation to clinical disease syndromes.
A CONCEPTUAL MODEL OF INDUCED IMMUNE PRIVILEGE
A diverse range of primary insults stimulate local inﬂammation,
including wounding, infections, pre-malignancies, radiation, vac-
cines, and chemical or biological toxins.However, themucosal sur-
faces of the respiratory, gastro-intestinal-tracts, and reproductive
tracts (especially the uterus during pregnancy) exhibit many fea-
tures of inﬂamed tissues during homeostasis. The ability of insults
to elicit potent innate and adaptive immunity varies considerably
depending on which tissue experiences the primary insult. In this
reviewwe focus onnatural and experimentally induced insults that
stimulate inﬂammatory responses with potent immune regula-
tory components as examples of where induced immune privilege
manifests. Previously, we proposed a model to explain how IDO
enzyme activity induced in local tissues as a response to inﬂam-
matory cues may create immune privilege (Mellor and Munn,
2008).We proposed four key checkpoints that promote and main-
tain immune privilege in local inﬂamed tissues. In this section,
we further develop this model in light of recent novel insights
(Figure 1).
CHECKPOINT A
Innate immune responses to inﬂammatory insults
Typically, microbial infections induce rapid release of pro-
inﬂammatory cytokines such as interferons (IFNαβ, IFNγ), tumor
necrosis factor (TNFα), interleukins (IL-1β, IL-6, etc.), and
chemokines by stromal cells and innate immune cells to provoke
effective adaptive immunity. However some inﬂammatory stim-
uli – including some microbes – elicit innate immune responses
that promote production of regulatory cytokines such as IL-10,
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FIGURE 1 | Potential regulatory checkpoints involved in induced immune privilege in local tissue microenvironments.
and transforming growth factor (TGFβ) that suppress local release
of pro-inﬂammatory cytokines and activate (or attract) immune
regulatory cells. Thus initial local responses to primary insults
exert profound inﬂuences on the subsequent course of immune
responses, and elucidating how cells resident in primary tissue
lesions respond to inﬂammatory cues is pivotal to understand
the source of immune privilege. For example, pre-malignancies
arise frequently in many tissues, but their ability to progress to
form tumors is acquired over long periods, and overt tumors
develop only when immune surveillance mechanisms are evaded
successfully. Similar considerations may apply to pathogens that
cause some persistent infections, though pathogens have proba-
bly evolved numerous mechanisms to evade – and even actively
suppress – innate immune surveillance mechanisms to induce
immune privilege.
In light of the considerations above it is probably no coin-
cidence that tumors and chronic infections are often associated
with induced local IDO expression because IDO has potent regu-
latory effects on immune and non-immune cell types (Uyttenhove
et al., 2003; Boasso, 2011;Makala et al., 2011). Ablating the IDO1
gene in mice also enhanced their resistance to tumor formation
in the standard of inﬂammation-dependent, carcinogen-induced
(DMBA/TPA) cancer model (Banerjee et al., 2008). The unrelated
enzyme tryptophan dioxygenase (TDO) is also expressed by some
tumors and, like IDO catalyzes oxidative tryptophan catabolism to
produce kynurenines (Opitz et al., 2011). Thus pre-malignant cells
expressing IDO or TDO may create immune privilege via (a) tryp-
tophandepletion to activate the general control non-derepressible-
2 (GCN2) dependent integrated stress response (ISR) to amino
acid withdrawal, and (b) kynurenine that binds to the aryl hydro-
carbon receptor (AhR). Early induction of these (and perhaps
other) metabolic processes may be critical steps in disease pro-
gression leading to the hypo-immune syndromes that characterize
tumor growth and chronic infections. In this regard it may be sig-
niﬁcant that UV-irradiation (UVB) creates skin edema and asso-
ciated inﬂammatory responses that include local IDO induction
(unpublished data). Interestingly, skin tanning in response toUVB
is mediated by the AhR (Jux et al., 2011), suggesting that exposure
to UVB irradiation has both desirable and detrimental effects due
to altered tryptophan metabolism. If these notions are correct
early treatments to block immune regulatory processes may be
effective in reducing the risk of contracting cancer and chronic
infections. However, it is important to stress that IDO may serve
dual functions as (a) an immune regulatory pathway that beneﬁts
developing tumors and pathogens, or (b) a host defense mecha-
nism that impedes tumor growth and microbial infections to the
beneﬁt of hosts. This is a key consideration as the dominant effects
of IDO at sites of inﬂammation may not be clear from simple
observation, and must be determined by appropriate manipu-
lation of experimental systems. For example, IDO is a frequent
component of chronic inﬂammation associatedwith autoimmune
destruction of healthy tissues, a correlation that could be inter-
preted as evidence that IDO promotes autoimmune pathology.
However, exposure to IDO inhibitors accelerates autoimmune
progression and potentiates disease severity in many autoimmune
disease models, revealing that IDO regulates destructive autoim-
munity in these syndromes. A helpful analogy to bear in mind is
that ﬁreﬁghters are always in attendance at ﬁres, but their presence
does not guarantee that ﬁres will eventually be brought under con-
trol to prevent total destruction. In summary, pre-malignancies
and pathogens may exploit innate “host” regulatory mechanisms
such as IDO to create local conditions that permit these agents
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of disease to evade immune surveillance during the early phases
of tumor development and infections. This paradigm implies that
IDO-mediated regulation that creates immune privilege may be
a key factor in disease progression, and not simply a target for
therapy to break immune privilege in patients with established
tumors and chronic infections. If correct, treatments that target
the IDO pathway may reduce the risk that pre-malignancies and
persistent pathogens establish immune privilege before they can
create pathologic disease. However, such interventions may also
interfere with homeostatic control of immunity to self-antigens
and innocuous antigens such as allergens, and it remains to be
determined if appropriate balances between hyper-immunity and
prevention of diseases due to hypo-immunity can be engineered
through early therapeutic interventions in individuals with high
risk proﬁles.
CHECKPOINT B
Antigen presentation and lymphocyte activation in local draining
lymph nodes
Presenting antigens to lymphocytes is necessary, but may not be
sufﬁcient to provoke adaptive immunity. Antigens in the local
inﬂammatory lesion, usually skin or a mucosal surface, are cap-
tured by resident tissue macrophages (Mφs) and dendritic cells
(DCs) via phagocytosis or pinocytosis. DCs are specialized to
undergo rapid maturation in response to innate inﬂammatory
cues (generated at Checkpoint A), and migrate to local drain-
ing lymph nodes (dLNs) where they present processed antigens,
in the form of peptides bound to surface MHC molecules, to
T cells. Hence mature DCs are “professional antigen presenting
cells” (APCs) that present antigens from (a) external sources such
as pathogens or innocuous substances (food, allergens commensal
microbes), and (b) tissue (self) antigens to T cells. T cells that rec-
ognize MHC/peptides in dLNs then undergo rapid activation and
differentiation to generate helper T cells that promote optimal
cellular and humoral responses, and effector (cytolytic) T cells.
The processes of acquiring, transporting, and presenting antigens
to T cells in dLNs may be subject to regulation in some settings
of inﬂammation. Inhibiting DC maturation or migration would
impede the process of generating helper/effector T cells. More-
over, immature DCs that enter dLNs may present antigens (signal
1) in the context of sub-optimal B7-CD28 co-stimulation (sig-
nal 2) leading to weak and ineffective T cell responses (Hackstein
andThomson,2004). Even fullymatureDCsmay suppress effector
responses if they acquire regulatory attributes that promote anergy
or apoptosis in T cells that respond to antigens they present, and
regulatory DCs may also induce naïve T cells to convert into regu-
latory T cells (Tregs; Reis e Sousa, 2006). Negative co-stimulatory
pathways (e.g., PD-1/PD-L, ICO/ICOS-L) and certain metabolic
processes (see below) may also attenuate effector responses and
promote tolerance in dLNs. For example, DCs expressing IDO
possess mature phenotypes but block effector T cell responses,
promote CD4 T cell conversion into Foxp3-lineage Tregs, and
activate pre-formed Tregs (Mellor et al., 2004, 2005; Munn et al.,
2004;Baban et al., 2005, 2009, 2011;Sharma et al., 2007; Chen
et al., 2008; Brenk et al., 2009;Chung et al., 2009). Thus DCs com-
petent to express IDO or other regulatory pathways in response
to appropriate cues may be pivotal in shaping adaptive immune
responses to primary insults contingent on whether they are – or
are not – induced to acquire regulatory phenotypes in particular
settings of inﬂammation.
CHECKPOINT C
Prevailing regulatory conditions in draining LNs
Lymphoid tissues exhibit differential capacities to promote and
support adaptive immunity. Thus skin dLNs typically support
robust adaptive immune responses to a range of topical insults
(though not all, see below), while LNs draining mucosal surfaces
generally support weak adaptive immune responses due to pre-
vailing physiologic conditions at these sites (Kraal et al., 2006).
Thus, even if tissue DCs mature efﬁciently, and migrate in large
numbers from primary lesions to dLNs their ability to promote
effective adaptive immune responses to antigens they present is
critically dependent on the prevailing physiologic status of dLNs.
Some factors and pathways discussed in Checkpoint B may also
help establish and sustain regulatory conditions that prevail in
some lymphoid tissues, and regulatory cytokines such as TGFβ
may be critical to maintain such conditions during homeosta-
sis. The constitutive presence of certain cytokines may dictate the
local “immunologic tone” in homeostatic tissues, but they may
also reﬂect local cellular states pre-determined during homeosta-
sis. For example, immunologic tone may be pre-determined by
the relative proportions of pre-formed Tregs in a given lymphoid
tissue, which in turn affects the ability of APCs to present anti-
gens in a regulatory or stimulatory context through differential
“licensing” of APCs by Tregs or helper T cells. As discussed below,
the presence or absence of DCs expressing IDO may be a pivotal
determinant of prevailing immunologic tone in lymphoid tissues.
CHECKPOINT D
Induced immune regulation in inﬂamed target tissues
Responses to primary insults elaborated via local dLNs may
include regulatory components that impact what happens in tar-
get tissues affected by the primary insult. Over time, certain cell
types with immune regulatory attributes may accumulate in pri-
mary lesions to dampen down initial pro-inﬂammatory responses.
Indeed, delayed suppression of overt immunity is considered
essential to attenuate induced immune responses as local infec-
tions are brought under control and pathogens are cleared from
primary lesions. Several cell types possessing a variety of regulatory
pathways may help down-regulate immune responses, including
(but probably not limited to) lymphocytes, myeloid cells (Mφs,
DCs), natural killer (NK) cells, mast cells, and enigmatic myeloid-
derived suppressor cells (MDSCs) and mesenchymal stem cells
found in many settings of inﬂammation where hypo-immunity
manifests (Ding et al., 2010; De Vries et al., 2011; Mantovani
et al., 2011;Murphy et al., 2011;Ostrand-Rosenberg et al., 2012). In
transplant settings tolerogenic factors that protect allografted tis-
sues are complex, involving immunologic and metabolic processes
required on a continuous basis, as disrupting these mechanisms
usually leads to graft rejection even after prolonged periods of
allograft acceptance (Cobbold, 2010). Thus regulatory cells and
factors such as cytokines and IDO that promote immune reg-
ulation may be essential to maintain hypo-immunity following
adaptive immune responses as well as mediating early responses
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that promote hypo-immunity (Checkpoint A). It remains to be
seen if similar processes promote and maintain immune privilege
in inﬂamed tissues.
IDO BIOCHEMISTRY AND METABOLIC EFFECTS ON IMMUNE
CELLS
IDO is a highly conserved, heme-containing intracellular enzyme
that catabolizes compounds containing indole rings such as the
essential amino acid tryptophan. Two closely linked, homologous
IDO genes (IDO1, IDO2) are located in syntenic regions of chro-
mosome 8 in humans and mice. IDO1 and IDO2 may respond to
distinct signals since their patterns of gene expression are not iden-
tical. IDO1 encodes functional IDO protein that regulates T cell
responses when expressed in some DCs while IDO2 is expressed
in other cell types. Unlike IDO genes, TDO gene expression is
controlled by stress factors such as glucocorticoids, not inﬂam-
matory IFNs. Here we focus on the role of IDO1 gene expression
immune regulation. Though IDO is expressed by few cell types
during homeostasis a number of cell types mediate IDO enzyme
activity in response to inﬂammatory insults including stromal,
hematopoietic, and tumor cells. Interferons type I (IFNαβ) and
II (IFNγ) are potent IDO inducers due to the presence of inter-
feron stimulated response element (ISRE) and interferon-gamma
activated sequence (GAS) elements in the proximal gene pro-
moters of mammalian IDO genes (Dai and Gupta, 1990; Chon
et al., 1995). Other molecular signals from cytokines (TGFβ, IL-
10), Toll-like receptor (TLRs), B7, CD200, GITR, OX40, PD-1,
and AhR ligands may also promote IDO expression, though in
some cases IDO induction may be an indirect response to IFNs
elicited by primary signals (see below). Mφs expressing IDO in
response to certain infections such as Toxoplasma also mediate
innate host defense. Though IDO does not affect sterile clear-
ance of Toxoplasma infections in mice, IDO ablation led to 100%
mortality showing that IDO plays a crucial regulatory role in host–
pathogen interactions in this chronic infection (Divanovic et al.,
2012). IDO was ﬁrst shown to regulate T cell immunity to fetal
tissues during pregnancy (essentially a tolerated allograft) since
treatment with the IDO inhibitor 1-methyl-tryptophan (1MT)
caused pregnancy failure in mice due to maternal T cell mediated
destruction of allogeneic but not syngeneic fetal tissues (Munn
et al., 1998; Mellor et al., 2001). Since then IDO activity has
been linked to tumor-induced tolerance, persistence of chronic
infections, and attenuation of autoimmune, and allergic disease
syndromes.
As mentioned above DCs expressing IDO suppress antigen-
speciﬁc T cell responses. IDO activity in DCs does not attenuate
antigen presentation and T cell activation but causes activated
T cells to undergo cell cycle arrest and apoptosis, or induce
anergy and promote Tregs conversion. IDO activity may sup-
press T cell responses in three ways: (a) tryptophan withdrawal,
(b) production of kynurenines, and (c) altered redox potentials
due to consumption of superoxide radicals (Figure 2). Reduced
access to tryptophan during T cell activation triggers cell cycle
arrest by activating GCN2 kinase, which senses reduced amino
acid levels when uncharged tRNA molecules bind to ribosomes.
GCN2 kinase phosphorylates eIF2α at serine 51 to inhibit general
protein synthesis, and activate downstream stress response genes
FIGURE 2 | Metabolic effects of IDO activity on immune cells.
such as CCAAT/enhancer-binding protein homologous protein
(CHOP) which has pro-apoptotic functions. T cells from GCN2-
deﬁcient mice were resistant to the regulation by DCs expressing
IDO (Munn et al., 2005), and resting Tregs from GCN2-deﬁcient
mice did not acquire regulatory phenotypes in response to DCs
expressing IDO (Sharma et al., 2007; Baban et al., 2009). Arginase
activity in Mφs had similar effects on T cells and Tregs indi-
cating that GCN2 kinase activation is a common downstream
pathway by which amino acid catabolism promotes immune reg-
ulation (Bronte and Zanovello, 2005; Rodriguez et al., 2007).
Some tryptophan catabolites made by IDO-expressing DCs also
possess regulatory attributes by inhibiting T cell proliferation,
inducing T cell apoptosis, and blocking differentiation of Th1
helper cells (Frumento et al., 2002; Terness et al., 2002;Fallar-
ino et al., 2003; Chen et al., 2008). Consistent with this notion
3-hydroxyanthranilic acid (3-HAA) blocked T cell responses and
promotedT cell apoptosis by depletion of intracellular glutathione
(GSH) and by inhibition of PDK1, which is an essential mediator
of CD28-induced NFκB activation (Lee et al., 2010). Recent stud-
ies showing that kynurenine binds to AhR and that AhR signaling
regulates T cell responses and activates Tregs also provide mecha-
nistic explanations for IDO-mediated T cell regulation (Quintana
et al., 2008; Vogel et al., 2008;Bankoti et al., 2010; Mezrich et al.,
2010; Opitz et al., 2011). T cells may also be sensitive to changes
in redox potential mediated by IDO activity in DCs. Reactive oxy-
gen species (ROS) produced by phagocytes and other activated
immune cells such as neutrophils have potent effects on cellmetab-
olism and biological functions. Thus, mice with a genetic defect
(pHox49-deﬁcient) in NADPH oxidase-dependent ROS produc-
tion exhibited defective IDO activity that contributed to T cell
hyperactivity in a model of pulmonary aspergillosis, analogous
to patients susceptible to chronic granulomatous disease (CGD;
Romani et al., 2008). In vitro studies also showed that treatment
of human NK cell line with IDO metabolite, l-kynurenine, sig-
niﬁcantly reduced cell viability through generation of ROS (Song
et al., 2011).
IDO activity also blocks functional re-programming of pre-
formed, resting Tregs into polyfunctional helper/effector (Th17) T
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cells in certain settings of inﬂammation. Thus, IDOactivity inDCs
activated GCN2 kinase in Tregs, and inhibited IL-6 production in
tumor dLNs and in mice treated with TLR9 ligands to induce
IDO (Baban et al., 2009; Sharma et al., 2009). Moreover, IDO-
mediated Treg activation in response to systemic TLR9 ligands was
dependent on regulatory cytokines (TGFβ, IL-10) and negative co-
stimulation via CTLA4/B7 and PD-1/PD-L interactions between
Tregs and DCs that maintained competence of DCs to express
IDO in response to TLR9-induced IFN type I signaling (Baban
et al., 2011). These data suggest that multiple pathways maintain
default responsiveness via IDO to create regulatory outcomes dur-
ing homeostasis, and that inﬂammatory signals must overcome
these default regulatory pathways to promote pro-inﬂammatory,
immune stimulatory outcomes. For example, vaccination with
antigen plus (low dose) TLR9 ligands promoted Treg conversion
into effector T cells, which were essential for initial priming of
effector CD8 T cells by cross-presented antigens (Sharma et al.,
2010). However IDO expression induced by established tumors
prevented Treg re-programming, indicating that IDO was critical
in regulating early effector T cell responses during inﬂammation
and that vaccines were rendered ineffective, unless IDO activity
was ablated. In human immunodeﬁciency virus (HIV) infected
patients, elevated IDO activity by myeloid DCs was associated
with loss of Th17 cells and increase of Tregs (Favre et al., 2010).
Thus IDO has a critical role in maintaining the balance of Tregs
and helper/effector T cells, and may be critical for pathogens to
persist in immunocompetent hosts despite host defense functions
of IDO in some infections.
IDO-COMPETENT DCs
Dendritic cells are the only APC type capable of activating naïve T
cells, underscoring their critical role in initiating T cell immu-
nity. Few DCs in humans and mice are competent to express
functional IDO. Though murine CD8− and CD8+ DC subsets
expressed IDO protein in response to IFNγ treatment, only CD8+
DCs produced kynurenine, indicating IDO enzyme activity (Fal-
larino et al., 2002). Systemic treatments with soluble CTLA4
(CTLA4-Ig) and relatively high doses of TLR9 ligands (CpGs)
were also able to induce CD8+ DCs to express functional IDO
by ligating B7 or TLR9 molecules and inducing IDO via IFNα
signaling in a rare, but distinctive subset of splenic CD19+ DCs
co-expressing CD8, the plasmacytoid DC (pDC) marker B220, as
well as CD19 and other B cell markers (Grohmann et al., 2002;
Mellor et al., 2003, 2005;Baban et al., 2005;Johnson et al., 2010).
In humans, monocyte-derived DCs competent to express IDO in
response to IFNγ were a discrete subset of DCs expressing the
chemokine receptor CCR6 and the pDC marker CD123 (Munn
et al., 2002), and human DCs expressing IDO in response to CpGs
also exhibited pDC attributes (Chen et al., 2008).
The relative paucity of IDO-competent DCs in mice (∼10%
of total splenic DCs) and humans is a technical problem. To help
counter this problem, we developed robust (MLR-based) assays to
detect T cell suppression mediated by IDO+ DCs from mice bear-
ing tumors or treated with IDO inducers (Table 1). Using these
DC suppression assays, and analogous assays to detect suppression
mediated by small numbers of Tregs from lymphoid tissues, we
determined that IDO+ DCsmediateT cell suppressionbyblocking
Table 1 | IDO pathway inhibitors and inducers.
Effect Compound Mechanism (pathway) Reference
IDO inhibitor d-1MT IDO pathway Hou et al. (2007)
MTH-Trp IDO enzyme Muller et al. (2005a)
Brassinin IDO enzyme Gaspari et al. (2006)
5l IDO enzyme Yue et al. (2009)
Imatinib PK inhibitor Balachandran et al. (2011)
IDO inducer Type I andType II IFNs* JAK/STAT (IDO promoter) Taylor and Feng (1991), Mellor et al. (2005)
CTLA4-Ig B7 ligand (FOXO3a) Baban et al. (2005), Fallarino et al. (2004b)
CD40-Ig IFNγ induction in CD8T cells Guillonneau et al. (2007)
LPS* TLR4 ligand (IFN type I) Fujigaki et al. (2006)
CpG* TLR9 ligand (IFN type I) Mellor et al. (2005)
Resiquimod* TLR7/8 ligand (IFN type I) Manches et al. (2008)
poly(I:C)* TLR3 ligand (IFN type I) Wang et al. (2011)
Dexamethasone* GITR ligand Grohmann et al. (2007)
CD200 CD200R ligand Fallarino et al. (2004a)
4-1BB IFN γ induction in CD8T cells Seo et al. (2004)
PGE2 Unknown Von Bergwelt-Baildon et al. (2006)
sCD83 Unknown Lan et al. (2010)
IgE/anti-IgE FceRI aggregation Von Bubnoff et al. (2002)
HDAC inhibitor* HDAC inhibition Reddy et al. (2008)
Dioxin* AhR ligand Vogel et al. (2008)
d-1MT, 1-Methyl-d-tryptophan; MTH-Trp, methyl-thiohydantoin-tryptophan; CTLA4, Cytotoxic T-Lymphocyte Antigen 4; LPS, Lipopolysaccharide; GITR, glucocorticoid-
inducedTNFR-related protein; HADC, histone deacetylase; AhR, aryl hydrocarbon receptor.
*Reagents with known toxic and/or pro-inﬂammatory (immune stimulatory) effects in vivo.
www.frontiersin.org May 2012 | Volume 3 | Article 109 | 5
Li et al. IDO in immune privilege
clonal expansion of activated T cell, and by activating pre-formed,
functionally quiescent (resting) Tregs to mediate bystander sup-
pression. A distinctive feature of IDO-activated Tregs from tumor-
bearing mice and mice treated with systemic TLR9 ligands was
that suppression depended on interactions between PD-1 and its
ligands PD-L1 and PD-L2. Intact GCN2 genes (in Tregs) were
essential for Tregs to activate in response to IDO activity in DCs,
emphasizing the critical role of tryptophan depletion in driving
regulatory outcomes (Sharma et al., 2007; Baban et al., 2009).
Increasing evidence also points to roles for tryptophan catabolites
in promoting regulatory outcomes since kynurenine is anAhR lig-
and that drives Treg conversion from naïve CD4 T cells (Mezrich
et al., 2010; Nguyen et al., 2010). Moreover, requirements for sig-
nals from CTLA4, PD-1, TGFβ, and IL-10 for CD19+ DCs to
up-regulate IDO in response to TLR9 ligands suggest that IDO-
competence is maintained by constitutive interactions between
CD19+ DCs and resting Tregs during homeostasis (Baban et al.,
2011). Loss of any one of these molecular pathways caused Foxp3-
lineage Tregs to undergo rapid functional re-programming into
helper/effector T cells expressing TNFα, IL-17 IL-2 and IFNγ,
probably due to IL-6 production which is suppressed by IDO
activity in DCs. Thus, the relative numbers of CD19+ DCs and
Tregs and several non-redundant molecular pathways may be key
factors that determine“immunologic tone”in particular lymphoid
tissues (Checkpoint C) by regulating the ability of Tregs to become
potent suppressor cells or polyfunctional helper/effector T cells in
response to inﬂammatory cues.
MANIPULATING IDO TO CREATE OR DESTROY IMMUNE
PRIVILEGE
Immune privilege helps protect tissues from damage mediated
by excess immune responses generated when inﬂammation low-
ers thresholds that keep innate autoimmunity in check during
homeostasis. In transplant settings artiﬁcial creation of immune
privilege to mimic local tolerance induced by tumors and some
pathogens that cause chronic infections is a key strategy to enhance
allograft survival. Hence,manipulating the IDO pathway to create
or destroy immune privilege offers potential therapeutic strategies
to treat a range of chronic inﬂammatory disease syndromes.
USING IDO PATHWAY INHIBITORS TO ATTENUATE ESTABLISHED
IMMUNE PRIVILEGE
Inhibiting the IDO pathway is a potential strategy to treat patients
with hypo-immune syndromes (cancer and chronic infections)
caused by induced immune privilege that permits persistence and
progression of tumors and pathogen infections in immunocom-
petent individuals. In this section we discuss recent progress in
developing new methods to inhibit IDO that may be effective in
treating patients with cancer and chronic infections. We focus on
the use of pharmacologic IDO pathway inhibitors to achieve this
goal, though strategies using si/shRNA to knockdown IDO gene
expression in speciﬁc cell or tissue types may be an alternative
approach to achieve similar goals (Zheng et al., 2006; Flatekval
and Sioud, 2009;Yen et al., 2009; Huang et al., 2011).
Cancer
At sites of tumor growth tryptophan catabolism mediated by IDO
in host APCs, or IDO, or TDO in tumor cells can promote and
sustain immune privilege. In humans, IDO1 expression in numer-
ous tumor cell types is a signiﬁcant predictor of poor prognosis
(Sakurai et al., 2004; Astigiano et al., 2005;Brandacher et al., 2006;
Ino et al., 2006;Riesenberg et al., 2007; Takao et al., 2007;Pan et al.,
2008). In murine models, transfection of immunogenic tumor cell
lines with recombinant IDO1 or TDO rendered them immuno-
suppressive and lethally progressive in vivo (Uyttenhove et al.,
2003; Pilotte et al., 2012). The role of IDO in tumor immuno-
suppression was initially investigated using the racemic mixture
of the IDO inhibitor 1MT (d,l-1MT). Thus d,l-1MT adminis-
tration to mice bearing tumors that over-expressed IDO due to
transfection or genetic deﬁciency of the tumor-suppressor Bin1
(leading to IDO1 over-expression) enhanced anti-tumor immu-
nity and slowed tumor growth (Friberg et al., 2002; Uyttenhove
et al.,2003;Muller et al., 2005b).Moreoverd,l-1MT treatment syn-
ergized with several chemo-immunotherapy regimens to enhance
anti-tumor effects in mice, as well as in regimens involving com-
bination with radiotherapy (Muller et al., 2005b; Hou et al., 2007).
A key question regarding d,l-1MT was whether both d and l
stereoisomers of 1MT were biologically active. Based on in vitro
assays using puriﬁed rabbit intestinal IDO l-1MT it was assumed
that l-1MT would be more effective than d-1MT as an IDO
inhibitor to promote T cell mediated anti-tumor immunity in vivo
(Peterson et al., 1994). Unexpectedly, d-1MT was as effective, or
more potent than l-1MT than the racemic mixture in restoring
proliferation of T cells suppressed by physiologic IDO+ pDCs
(Munn et al., 2002). In addition, d-1MT was more effective than
l-1MT in reversing suppression of T cell proliferation created
by IDO+ human monocyte-derived DCs and murine DCs from
tumor-dLNs, and restored proliferation of primary CD4+ and
CD8+ T cells blocked by IDO+ ﬁbroblast cells (Hou et al., 2007;
Forouzandeh et al., 2008). d-1MT was also more effective than l-
1MT as an anti-cancer agent in chemo-immunotherapy regimens
in mouse models of transplantable melanoma and transplantable
and autochthonous breast cancer (Hou et al., 2007). Despite these
indications of superior d-1MT efﬁcacy as an anti-tumor drug the
molecular target of d-1MT has not been deﬁned as d-1MT did not
inhibit enzyme activity of recombinant human and murine IDO1
protein in cell-free assays, and IDO enzyme activity in human
tumor cell lines and cell lines transfected with IDO1 genes (Lob
et al., 2009). Nevertheless the anti-tumor and T cell enhancing
effects of d-1MT were abrogated in the absence of functional
IDO1 genes, and IDO1-deﬁcient mice developed tumors that were
not sensitized to chemo-immunotherapy involving d-1MT (Hou
et al., 2007). Thus, the pharmacologic effects of d-1MT mani-
fested only when the IDO1 pathway was intact, and d-1MT targets
DCs that attenuate T cell responses. Several mechanisms could
explain how d-1MT inhibits the IDO pathway in DCs while not
inhibiting IDO enzyme activity directly as follows; (a) inhibition
of high afﬁnity tryptophan transporters in DCs to block substrate
supply to IDO; (b) inhibition of uncharacterized IDO1 enzyme
isoforms produced by RNA editing, post-translational modiﬁ-
cations or association with other proteins into supramolecular
complexes inDCs; (c)d-1MTconversion into the active enzymatic
inhibitor l-1MT; (d) mimicking signals of tryptophan sufﬁciency,
or blocking signals of tryptophan deﬁciency or downstream sig-
nals elicited by tryptophan metabolites in DCs. Regarding the last
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mechanism, d-1MT may block downstream GCN2 activation or
AhR signaling mediated by tryptophan withdrawal and kynure-
nine production. Thus d-1MT may target the “IDO pathway”
but not IDO enzyme. Interestingly, the PK inhibitor Imatinib
mesylate (Gleevec), an effective treatment for patients with gas-
trointestinal stromal tumor (GIST), blocked PK-mediated IDO
induction in a mouse model of GIST (Balachandran et al., 2011).
In addition halofuginone (Hf), a derivative of the bioactive com-
poundFebrifugine found in a traditional Chinese herbalmedicine,
bypasses IDO by activating GCN2 kinase to block effector Th17
responses (Sundrud et al., 2009). Recently, the molecular target of
Hf was identiﬁed as glutamyl-prolyl-tRNA synthetase (EPRS), and
Hf was shown to inhibit prolyl-tRNA synthetase activity (Keller
et al., 2012). Thus Imatinib and Hf act, at least in part, by targeting
components of the IDO pathway but not IDO directly to pheno-
copy IDO-mediated effects, and d-1MT may have a similar mode
of action. It remains to be seen if d-1MT will be effective in can-
cer patients. Early indications from Phase I clinical trials hinted at
efﬁcacy thatmanifested as hypophysitis (inwhich the immune sys-
tem attacks the pituitary gland) in some patients who had received
prior antibody immunotherapy treatment (Garber, 2012). Anti-
tumor efﬁcacy is more likely to manifest when d-1MT is used in
combination with other anti-cancer treatments because blocking
IDO does not incite anti-tumor immunity per se. The anti-tumor
and immune enhancing effects of d-1MT treatment were also
replicated by administering other compounds that inhibit IDO1-
encoded IDO enzyme activity in vitro and in IDO1-transfected
cells such as 5-Br-brassinin, menadione, methyl-thiohydantoin-
tryptophan, and analogs of phenylimidazole (Muller and Scherle,
2006; Banerjee et al., 2008;Kumar et al., 2008). Recently, hydrox-
yamidine inhibitors were also reported to suppress tryptophan
catabolism and possess anti-tumor activity (Yue et al., 2009; Kob-
lish et al., 2010;Liu et al., 2010), and TDO inhibitors may also be
effective anti-tumor drugs based on a recent report that Kyn from
tumor cells expressing TDO promoted tumor-induced immune
privilege via AhR signaling (Opitz et al., 2011).
Chronic infections
The use of IDO inhibitors to enhance host immunity to infec-
tious pathogens may seem paradoxical based on ﬁndings that Mφs
expressing IDOcanmediate innate host defense in some infectious
disease settings such asToxoplasma,Trypanosoma,Chlamydia, and
(Vincendeau et al., 1999; Njau et al., 2009;Knubel et al., 2010).
Moreover IDO inhibition failed to restrict herpes simplex virus
type 1 (HSV-1) replication or latency, and reactivated latent tox-
oplasma infections in mice leading to mortality (Divanovic et al.,
2012). Nevertheless from the perspective of some pathogens, the
disadvantages of needing to survive against IDO-mediated innate
host defense may be outweighed by the potential advantages of
IDO-mediated regulation of host adaptive immunity. For exam-
ple HIV-1, which causes AIDS, is a potent IDO inducer leading
to altered Th17/Treg balance that may favor HIV-1 persistence
(Boasso et al., 2007, 2009;Favre et al., 2010) In effect, HIV-1 may
be an example of a pathogen that has evolved to exploit the
IDO pathway as a means to prevent host-mediated viral clear-
ance. If correct, this notion suggests that IDO inhibitors may
destroy HIV-1-induced immune privilege that suppresses natural
and vaccine-induced anti-HIV-1 immunity. Consistent with this
idea,Boasso et al. (2009) reported that combined d-1MT,and anti-
retroviral therapy (ART) lowered virus titers in simian immun-
odeﬁciency virus (SIV)-infected rhesus macaques. Similar effects
of d-1MT on lowering parasite burdens were observed in mice
infected with Leishmania major (Makala et al., 2011; Divanovic
et al., 2012). In vitro data showed 1MT treatment restored M.
tuberculosis-speciﬁc CD4 T cell effector functions by increasing
IFNγ production (Li et al., 2011). These observations support the
use of IDO pathway inhibitors as a possible method to destroy
pathogen-induced immune privilege; however, opposing effects
of IDO pathway inhibitors on host defense mechanisms that
maintain stable host–pathogen relationships developed over evo-
lutionary time may complicate efforts to apply this basic approach
in clinical settings.
Vaccines
Regulatory pathways that create and maintain immune privilege
may block or attenuate responses to vaccines designed to induce
protective and therapeutic immunity in settings of cancer and
chronic infections. Established tumors and infections are notori-
ously resistant to vaccine-induced immunity due to the intensity
of local suppressivemechanisms.However, a common assumption
is that regulatory pathways do not impede responses to prophy-
lactic vaccines. This assumption may not be entirely correct in
some cases. For example, the vaccine adjuvant effects of the NK
cell inducer and CD1d ligand alpha-galactosylceramide (αgalcer)
was masked by rapid induction of IDO in mice vaccinated with
inactivated inﬂuenzaAvirus, and co-treatmentwith IDO inhibitor
(1MT) augmented primaryT cell responses to vaccination, though
did not enhance memory T cell generation (Guillonneau et al.,
2009). It is unclear why IDO was induced rapidly in this model;
one potential explanation is that IFNγ from activated NK cells
stimulated local IDO expression, though a subset of DCs express-
ing CD1d may respond directly to αgalcer by expressing IDO.
In a recent report SIV infected macaques treated with a SIV-
based vaccine and ART simultaneously succumbed to lethal acute
pancreatitis and hyperglycemic coma when vaccination and ART
were combined with d-1MT and CTLA4 mAb blockade to inhibit
immune regulatory pathways (Vaccari et al., 2012). This study
revealed that IDO and/or CTLA4 regulatory pathways impede cat-
astrophic host responses to ART-related toxicities, and sounds a
precautionary note that interfering with regulatory pathways dur-
ing vaccination can provoke undesirable toxicities. Nevertheless,
optimal vaccine design should take into account the effects of host
regulatory pathways, especially in therapeutic settings when estab-
lished immune privilege may completely eliminate any beneﬁcial
effects of vaccine administration where it matters, namely at local
sites of tumor growth and infection.
USING IDO INDUCERS AND TRYPTOPHAN METABOLITES TO CREATE
IMMUNE PRIVILEGE
Autoimmunity, allergy, and transplantation are all hyper-immune
syndromes in which excessive immunity damages healthy tissues.
Regulatory pathways are often chronically activated in such set-
tings. Though enhanced regulation may delay disease progression
and onset and reduce the severity of disease pathology enhanced
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regulation may not prevent disease progression completely; a
pertinent analogy is driving a car with the parking brake on.
Thus, IDO enzyme activity is often elevated in hyper-immune
syndromes (increased Kyn in blood and tissues) and IDO slows
but does not prevent disease progression. Nevertheless, enhancing
IDO expression and activity may be a potential strategy to amelio-
rate hyper-immune syndromes and protect healthy tissues in the
same way that IDO-mediated dominant regulation protects allo-
geneic fetal tissues from destruction by maternal T cell cells. Three
broad strategies may help achieve this goal; (a) IDO gene transfer
into vulnerable tissues, (b) treatment with reagents that induce
IDO, and (c) treatment with reagents that mediate downstream
regulatory effects of IDO. In this section we discuss progress in
developing these complementary strategies to treat hyper-immune
syndromes.
IDO gene transfer
IDO gene transfer to drive increased IDO expression in local tis-
sues is the most direct strategy to attenuate hyper-immunity. IDO
gene transfer into donor tissues prolonged allograft survival in
corneal (Beutelspacher et al., 2006), cardiac (Li et al., 2007), and
lung transplantation (Swanson et al., 2004; Liu et al., 2006a,b,
2007, 2009). The mechanism of enhanced allograft survival is not
fully understood, but correlated with reduced clonal expansion of
donor-speciﬁc effector T cells and attenuated effector functions
of CD8 T cells that were generated and migrated to donor tis-
sues expressing increased IDO (Liu et al., 2009). Reduced cytokine
levels, T cell proliferative capacity, and increased Tregs were asso-
ciated with protection of cardiac allografts transfected with IDO
(Yu et al., 2008). Regardless of the exact mechanisms of transplant
protection in these models, these ﬁndings support the use of IDO
gene transfer as a potential means to protect healthy tissues in
clinical settings. However, the creation of more robust immune
privilege by over-expressing IDO may have unintended and unde-
sirable consequences thatmay preclude clinical application such as
increased risks of infection and tumor formation in tissues where
IDO activity is artiﬁcially and constitutively elevated.
IDO inducing reagents
Table 1 lists some biologic and pharmacologic reagents that have
been reported to induce IDO activity in mice or cell lines. A key
consideration from a clinical perspective is that reagents to induce
IDO must have minimal toxicities, as it is likely that extended
(chronic) treatmentswill be needed to attenuate establishedhyper-
immune disease syndromes. This consideration precludes the use
of many reagents listed in Table 1 due to known toxicities. For
example, type I and II IFNs that induce IDO via receptors dis-
tributed on many cell types via JAK–STAT signaling pathways
have documented toxicities. However, IFN type I is the current
standard-of-care for some hyper-immune syndromes, despite the
undesirable side-effects of chronic exposure to exogenous IFN
type I. Thus, IFNβ is used to treat patients with multiple sclerosis
(MS), and pegylated-IFNα is used to treat patients with hepati-
tis C virus (HCV) infections in combination with Ribovirin, a
broad range anti-viral drug (Masarone and Persico, 2011). The
mode of action of type I IFNs in these settings is not fully under-
stood. However signaling via IFN type I receptors on myeloid
cells attenuated experimental autoimmune encephalitis (EAE) dis-
ease progression and severity in mice, a widely accepted model
of MS (Prinz et al., 2008). Type I IFNs may be pivotal regula-
tors of host immunity in a range of autoimmune and chronic
infections diseases such as HIV and HCV. For this reason pDCs
may be critical mediators of hyper-immune syndromes since they
are major (but not exclusive) sources of type I IFNs, especially
in response to pathogen-associated molecular patterns (PAMPs)
such as TLRs. It may be pertinent that IDO-competent DCs in
humans and mice exhibit attributes that overlap with those of
conventional pDCs, as well as other lymphoid and myeloid sub-
sets (Munn et al., 2002; Chen et al., 2008;Johnson et al., 2010).
Nevertheless, the role of IFNs, and the cells that produce IFNs, in
hyper-immune syndromes is far from clear as IFNs mediate mul-
tiple downstream effects that encompass immune stimulatory and
immune regulatory pathways.
TheB7 (CD80/86) ligandCTLA4-Igwas designed as reagents to
block co-stimulation required to generate effector T cells. CTLA4-
Ig induces someDCsubsets to express IDOandacquire tolerogenic
phenotypes due to “reverse signaling” via B7 molecules. Thus B7
ligands may promote immune privilege by co-stimulatory block-
ade and by inducing DCs to express IDO. B7 ligands approved for
clinical treatment of hyper-immune syndromes may not induce
IDO in humans as poorly deﬁned structural features may be crit-
ical for reverse signaling via B7 to induce IDO. Hence, it is not
clear to what extent the potential IDO inducing attributes of B7
ligands may account for their clinical efﬁcacy as immune mod-
ulators. A key issue is that reagents for clinical use are based on
human proteins that may not interact with homologous human
and mouse receptors in identical ways. In our experience CTLA4-
Ig isoforms engineered with human sequences and with modi-
ﬁed immunoglobulin constant (Fc) domains do not induce IDO
in mice. Hence the co-stimulatory blockade attributes of such
reagents may manifest in mice but IDO-mediated effects will not.
It remains to be seen if B7 ligands engineered speciﬁcally to induce
IDO in humans are effective immune modulators in clinical set-
tings of hyper-immune syndromes. These points notwithstanding,
a recent study in mice revealed that combined CTLA4-Ig (abat-
acept) and donor-speciﬁc transfusion (DST) therapy promoted
heart allograft acceptance in an IDO and Treg dependent man-
ner (Sucher et al., 2012). Thus IDO induction, particularly in
DCs, is a pivotal checkpoint that can promote immune privilege,
though factors that control IDO induction in DCs are not fully
understood.
Several TLR ligands stimulate IDO expression and enzyme
activity in mice. The TLR4 ligand LPS induced IDO in human
peripheral blood mononuclear cells, THP-1, and U937 cell lines,
and mouse bone marrow derived DCs (Fujigaki et al., 2006; Jung
et al., 2007). LPS also induced human monocyte-derived DCs to
express IDO, which promoted DC maturation and Treg differen-
tiation (Hill et al., 2007). TLR9 ligands (CpGs) also stimulated
mouse and human DCs to express IDO and acquire tolerogenic
phenotypes by autocrine/paracrine type I IFN signaling in mice
(Baban et al., 2005; Mellor et al., 2005; Chen et al., 2008). As
a consequence, TLR9 ligands promoted naïve CD4 T cells to
differentiate (convert) into Tregs, and caused pre-formed (rest-
ing) Tregs to acquire potent regulatory phenotypes (activate) via
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IDO (Baban et al., 2009, 2011). Despite these examples of TLR-
mediated immune regulation, TLR ligands have well-documented
pro-inﬂammatory and immune stimulatory attributes that pre-
clude their use as immune modulators in clinical settings of
hyper-immunity.
Other IDO inducing reagents include histone deacety-
lase (HDAC) inhibitors and dexamethasone that ligates
glucocorticoid-induced TNF receptor (GITR; Grohmann et al.,
2007; Reddy et al., 2008). Polyinosinic–polycytidylic acid
[poly(I:C)], a synthetic double stranded RNA analog and TLR3
ligand, induced human trophoblast cells to express IDO (Wang
et al., 2011). Surface ligand/receptors including CD200, 4-1BB,
and the eicosanoid prostaglandin E2 (PGE2) were also reported to
induce IDO (Fallarino et al., 2004a; Seo et al., 2004;Von Bergwelt-
Baildon et al., 2006). Recently, the immunomodulatory reagent
soluble CD83 (sCD83) was reported to be an IDO inducer, and
the tolerizing effects of sCD83 in a murine renal transplant model
were blocked by IDO inhibitor (Ge et al., 2010; Lan et al., 2010).
Recently, we discovered that systemic treatment of mice with
nanoparticles containing the cationic polymer polyethylenimine
(PEI) complexed with DNA stimulated IDO expression in a range
of mouse tissues including lymphoid tissues (manuscript submit-
ted). This response was unexpected as DNA/PEI nanoparticles
elicit well-documented pro-inﬂammatory and immune stimu-
latory responses that promote anti-tumor immunity (Rodrigo-
Garzon et al., 2010). IDO activity was induced in splenic DCs,
which activated resting Tregs via IDO and blocked antigen-speciﬁc
T cell responses to vaccineswithin 24 hof treatmentwithDNA/PEI
nanoparticles. These responses were dependent on type I, but not
type II IFN signaling. Moreover, the presence of TLR9 ligands
(CpG motifs) in bacterial (plasmid) DNA was not required to
induce IDOor type I IFN.RemovingTLR9 ligands abrogated rapid
and uniform activation of NK cells, which released large amounts
of IFNγ into serum in response to DNA/PEI nanoparticles con-
taining immune stimulatory bacterial plasmid DNA containing
TLR9 ligands. Treating mice with DNA/PEI nanoparticles also
reduced the severity of antigen-induced arthritis, and prevented
Type 1 Diabetes (T1D) progression and onset in non-obese dia-
betic (NOD) female mice prone to T1D onset. In ongoing studies,
we are addressing the mechanism of IDO induction following
DNA/PEI nanoparticle treatment, and engineering biodegradable
isoforms of DNA/PEI nanoparticles as potential reagents to treat
clinical hyper-immune syndromes that promote immuneprivilege
by inducing IDO and activating Tregs.
In summary, IDO inducing reagents offer promising new
approaches to slow, prevent, or reverse hyper-immune syndromes.
Mechanisms of IDO induction and the cell types induced to
express IDO by these reagents have are not well-documented for
all IDO inducing reagents, and further studies will be necessary
to evaluate if these reagents can create robust tolerogenic pheno-
types in immune cells to create and sustain immune privilege that
protects healthy tissue at risk from hyper-immunity.
Tryptophan metabolites
Some tryptophan catabolites generated and released by cells
expressing IDO or TDO possess immunomodulatory attributes
that may promote regulation in inﬂamed tissues and associated
dLNs to create and maintain local immune privilege. Combined
treatment with Kyn and 3-hydroxy-anthranilic acid (3-HAA) pro-
longed allograft survival in a rat allogeneic skin transplant model
(Bauer et al., 2005), and 3-HAA treatment inhibited PDK1 activa-
tion and promoted T cell apoptosis to suppress T cell-mediated
lung pathology in a murine model of asthma (Hayashi et al.,
2007). IDO-mediated elevation of Treg:Th17 ratios characteris-
tic of the progressive chronic inﬂammatory state that manifests
during active HIV disease may also be mediated in part by 3-HAA,
based on the ﬁnding that 3-HAA replicated this phenotype in vitro
(Favre et al., 2010). Metabolic interplay between IDO and AhR
signaling is mediated by tryptophan metabolites as Kyn is an AhR
ligand, and AhR ligands such as Kyn, 2-(1’H-indole-3’-carbonyl)-
thiazole-4-carboxylic acid methyl ester (ITE) a natural AhR ligand
found in lungs, and the artiﬁcial AhR ligand iVAG539 induce IDO
expression in DCs; in addition, Kyn promotes Treg conversion,
possibly by direct AhR-mediated effects on Tregs or indirectly by
inducing DCs to express IDO (Song et al., 2002; Hauben et al.,
2008;Vogel et al., 2008; Mezrich et al., 2010;Nguyen et al., 2010;
Opitz et al., 2011). These observations suggest that the IDO and
AhR pathways reinforce regulatory responses via positive feedback
loops involving tryptophan catabolites that are AhR ligands and
other AhR ligands that induce IDO. The metabolic effects of AhR
ligands on inﬂammatory responses by DCs were the subject of a
recent review (Bankoti et al., 2010).
In summary, cells expressing functional IDO or TDO may
modulate local immune effector functions by stimulating AhR
in innate and adaptive immune cells, such as T cells, Th17, Tregs,
and DCs, which reinforces IDO-mediated regulatory phenotypes
in these cells. AhR expressed on non-immune cells including
lung epithelial cells, liver hepatocytes, and endothelial cells may
also mediate cell responses in tissue development, physiological
function, and immune responses (Walisser et al., 2005; Chiba
et al., 2011, 2012), indicating ubiquitous inﬂuences of trypto-
phan metabolites on both hematopoietic and non-hematopoietic
cells. The relative importance of the immune modulatory effects
of IDO-mediated tryptophan withdrawal to trigger the ISR in
immune cells and production of tryptophan catabolites is not
known. However these novel insights identify several metabolic
pathways that create and sustain immune privilege, thereby pro-
viding new therapeutic targets to disrupt (or reinforce) immune
privilege according to clinical need. As described above, Ima-
tinib and Hf are already examples of compounds that target the
IDO pathway indirectly, though with diametric effects on T cell
immunity. These ﬁndings reinforce the hypothesis that altered
amino acid metabolism at sites of local inﬂammation is a pivotal
immune control mechanism that helps create and sustain immune
privilege.
SUMMARY AND PROSPECTS
In this review we summarize key recent developments relating
to the concept that induced immune privilege explains differ-
ential immunogenicities observed at local sites of inﬂammation.
Clearly interactions between small numbers of innate and adaptive
immune cells in microenvironmental niches exert profound inﬂu-
ences on immune outcomes and disease progression that have not
been fully appreciated. This knowledge deﬁciency arose because
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key initiating events are far removed in time, and perhaps in
space too from their measurable consequences in terms of dis-
ease progression and onset. The application of new imaging tools
to examine interactions between small numbers of cells that lead
to measurable metabolic changes has potential to improve under-
standing of the fundamental biochemical and metabolic changes
that explain immunologic outcomes relevant to chronic inﬂam-
matory diseases. It is also clear that we are only just beginning to
understand how initial responses to inﬂammatory insults in tis-
sues, and the prevailing immunologic tone of lymphoid tissues
draining such tissues integrate information about the primary
insult that shapes subsequent responses in the innate and adaptive
immune systems. Some immune modulatory drugs that interfere
with processes that create local immune privilege are already
approved for clinical use, and many others are in the pipeline, with
more potential targets still to be considered. It will be interesting
to see how these new immunotherapies fare in clinical settings,
and how this ﬁeld develops based on data from clinical trials and
basic research.
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